• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Cell Rep . Mechanisms that promote the evolution of cross-reactive antibodies upon vaccination with designed influenza immunogens

tetano

Editor, Senior Moderator
Cell Rep


. 2023 Mar 1;42(3):112160.
doi: 10.1016/j.celrep.2023.112160. Online ahead of print.
Mechanisms that promote the evolution of cross-reactive antibodies upon vaccination with designed influenza immunogens


Leerang Yang[SUP] 1 [/SUP], Timothy M Caradonna[SUP] 2 [/SUP], Aaron G Schmidt[SUP] 3 [/SUP], Arup K Chakraborty[SUP] 4 [/SUP]



Affiliations

Abstract

Immunogens that elicit broadly neutralizing antibodies targeting the conserved receptor-binding site (RBS) on influenza hemagglutinin may serve as candidates for a universal influenza vaccine. Here, we develop a computational model to interrogate antibody evolution by affinity maturation after immunization with two types of immunogens: a heterotrimeric "chimera" hemagglutinin that is enriched for the RBS epitope relative to other B cell epitopes and a cocktail composed of three non-epitope-enriched homotrimers of the monomers that comprise the chimera. Experiments in mice find that the chimera outperforms the cocktail for eliciting RBS-directed antibodies. We show that this result follows from an interplay between how B cells engage these antigens and interact with diverse helper T cells and requires T cell-mediated selection of germinal center B cells to be a stringent constraint. Our results shed light on antibody evolution and highlight how immunogen design and T cells modulate vaccination outcomes.

Keywords: CP: Immunology; affinity maturation; antigen capture; antigen valency; helper T cell; immune focusing; immunogen design; in silico; mechanism; selection.
 
Back
Top Bottom